Gerade im British Medical Journal – online entdeckt, hat FEM die Site auf die Schnelle „komplett kopiert“.
Die Bearbeitung und teilweise Übersetzung folgt später.
FEMINISSIMA ist der Ansicht, die Meldung an sich ist so wichtig und spannend –
damit würde also ASPIRIN nicht nur wie bislang bekannt, bei Herzbeschwerden helfen, sondern auch bei Krebs-Arten wie Darm, Magen und Brust –
bleibt dran.
Home Help Search/Archive Feedback Table of Contents
——————————————————————————–
PDF of this article
Email this article to a friend
Respond to this article
PubMed citation
Related articles in PubMed
Download to Citation Manager
Search Medline for articles by:
Dyer, O.
Alert me when:
New articles cite this article
Collections under which this article appears:
Cancer: gastroenterological
Cancer:other
BMJ 2003;326:565 ( 15 March )
News
Aspirin could be used to prevent cancer
Owen Dyer, London
Three recently published studies indicate that aspirin, already enjoying a second lease of life in the prevention of heart disease, may soon become a first line of defence against cancer.
Two prospective, placebo controlled studies published in the New England Journal of Medicine (2003:348;883-90 and 891-9) looked at patients at risk of colorectal cancer. Both studies found a clear benefit from aspirin in reducing the frequency of new colorectal polyps.
The second of these studies, led by John Baron of Dartmouth Medical School, Hanover, New Hampshire, followed 1084 patients with a history of polyps and examined the patients by colonoscopy about three years after their entry into the study. The patients were split into three arms: a placebo group, a low dose group taking 81 mg aspirin daily, and a group taking 325 mg daily.
Most of the benefit was in the low dose group. The unadjusted risk ratios for new polyps were 0.81 in the low dose group (95% confidence interval, 0.69 to 0.96) and 0.96 in the high dose group (0.81 to 1.13)
When only large or malignant polyps were considered, however, the benefits were clearerrisk ratios of 0.59 (0.38 to 0.92) in the low dose group and 0.83 in the high dose group (0.55 to 1.23).
The other study of colorectal cancer, led by Professor Richard Schilsky of the University of Chicago, followed 517 patients with previous malignant disease, dividing them into placebo and 325 mg treatment groups. Although this study lasted only a year, the researchers found a risk ratio for new polyps of 0.65 (0.46 to 0.91) in the treatment group.
Dr Cristina Bosetti of the Mario Negri pharmacological research institute in Milan, who led the Italian research, speculated at a press conference that aspirin’s inhibition of the inflammatory enzyme cyclo-oxygenase-2 is the key to the drug’s apparent protective effect. „The effect of aspirin can also be seen in other cancers, because cyclo-oxegenase is also implicated in cancer of the stomach and breast cancer. If this is the mechanism of action the effect of aspirin could be similar for these cancers,“ she said.
Meanwhile an Italian study published in the British Journal of Cancer (2003;88:672-4)[CrossRef][Medline] found that long term use of aspirin dramatically reduced the incidence of tumours of the mouth, throat, and oesophagus. The research pooled data from three smaller studies to create a patient base of 965 cancer patients and 1779 controls. After controlling for factors such as smoking and diet, the researchers found that the incidence of the three types of cancer in people who had taken aspirin regularly for at least five years was a third that in people who had not taken aspirin (odds ratio 0.33 (0.13 to 0.82)).
(Credit: DAVID M MARTIN/SPL )
Aspirin could reduce incidence of colorectal polyps
——————————————————————————–
© 2003 BMJ Publishing Group Ltd
PDF of this article
Email this article to a friend
Respond to this article
PubMed citation
Related articles in PubMed
Download to Citation Manager
Search Medline for articles by:
Dyer, O.
Alert me when:
New articles cite this article
Collections under which this article appears:
Cancer: gastroenterological
Cancer:other
——————————————————————————–
Home Help Search/Archive Feedback Table of Contents
© 2003 BMJ Publishing Group Ltd